| Renal Cell Carcinoma

Bavencio vs Sutent

Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.

Deep comparison between: Bavencio vs Sutent with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsSutent has a higher rate of injection site reactions vs Bavencio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Sutent but not Bavencio, including UnitedHealthcare

Category

Bavencio

Sutent

At A Glance

RouteIV infusion

FrequencyEvery 2 weeks

ClassPD-L1 blocking antibody

RouteOral

FrequencyDaily

ClassMulti-targeted RTK inhibitor

Indications

Merkel cell carcinoma
Urothelial Carcinoma
Renal Cell Carcinoma

Gastrointestinal Stromal Tumors
Renal Cell Carcinoma
Well Differentiated Pancreatic Endocrine Neoplasm

Dosing

Merkel cell carcinoma, Urothelial Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.

Renal Cell Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity.

Gastrointestinal Stromal Tumors, Renal Cell Carcinoma 50 mg orally once daily on Schedule 4/2 (4 weeks on, 2 weeks off); adjuvant RCC limited to a maximum of nine 6-week cycles.

Well Differentiated Pancreatic Endocrine Neoplasm 37.5 mg orally once daily until disease progression or unacceptable toxicity.

Contraindications

—

Drug Interactions

189View drug interactions

1265View drug interactions

Adverse Reactions

Most common (>=20%) fatigue, musculoskeletal pain, diarrhea, hypertension, nausea, rash, infusion-related reaction, cough, constipation, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, hepatotoxicity, dyspnea, abdominal pain, urinary tract infection, headache

Serious immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, neurological toxicities), infusion-related reactions, complications of allogeneic HSCT, major adverse cardiovascular events

Postmarketing neutropenia, sclerosing cholangitis

Most common (>=25%) Fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, thrombocytopenia.

Serious Hepatotoxicity, cardiovascular events, QT interval prolongation and Torsade de Pointes, hemorrhagic events, tumor lysis syndrome, thrombotic microangiopathy, proteinuria, dermatologic toxicities, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw, impaired wound healing.

Postmarketing Hemorrhage associated with thrombocytopenia, esophagitis, acalculous cholecystitis, hypersensitivity reactions including angioedema, serious infection, fistula formation, myopathy/rhabdomyolysis, renal impairment/failure, pulmonary embolism, pleural effusion, pyoderma gangrenosum, arterial aneurysms/dissections/rupture, arterial thromboembolic events.

Pharmacology

Avelumab is a human IgG1 lambda monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors on T cells to restore anti-tumor immune responses; it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.

Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) including PDGFRalpha/beta, VEGFR1/2/3, KIT, FLT3, CSF-1R, and RET, which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Bavencio